MedTrace Logo

Once Daily 3TC, Efavirenz and ddI for HIV Infection

NCT00214435 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2005-10-25

No results posted yet for this study

Summary

Poor compliance is thought to be a major cause of treatment failure. The TEddI study is a randomised, multi-centre, open-label study in well-controlled treatment-experienced HIV-infected patients to assess compliance with a once-daily regimen of antiretroviral therapy versus continuation of current anti-retroviral regimen delivered at least twice daily.

Conditions

  • HIV Infection
  • AIDS

Interventions

DRUG

once daily minimum 3-drug regimen of anti-retroviral medications

Sponsors & Collaborators

Principal Investigators

  • David A Baker, MB ChB · 407 Doctors

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214435 on ClinicalTrials.gov